Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2014

01.06.2014 | Original Article – Clinical Oncology

The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre

verfasst von: Lawson Ung, Terence C. Chua, David L. Morris

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

In the setting of colorectal cancer, female gender has been associated with superior long-term outcomes. Our aim is to investigate the gender differences for metastatic epithelial neoplasms of the appendix treated by cytoreductive surgery (CS) and intraperitoneal chemotherapy (IPC).

Methods

The survival outcomes of patients treated with CS/IPC from 1996 to 2013 at St. George Hospital, Sydney, Australia, for peritoneal metastases of appendiceal origin were retrospectively analysed.

Results

Two hundred and fifty-seven consecutive patients were followed for a median of 35.3 months. Baseline characteristics between genders were comparable, including age (p = 0.13) and peritoneal cancer index (p = 0.94). Median overall survival (OS) and progression-free survival (PFS) was not reached (NR) and 44.4 months, with a 3-, 5- and 10-year survival of 82, 74 and 64 %. OS and PFS for females was NR and 50.7 months, compared to NR (p = 0.007) and 31.5 months for males (p = 0.07). Three-, 5- and 10-year survival rates for females were 88, 84 and 72 % compared to 74, 61 and 53 % for males.

Conclusion

Observed gender differences for neoplasms of the appendix may direct future research in gender-specific tumour markers and the development of adjuvant therapies to improve patient outcomes.
Literatur
Zurück zum Zitat Andreasson H, Wanders A, Sun XF, Willen R, Graf W, Nygren P, Glimelius B, Zhang ZY, Mahteme H (2012) Histopathological classification of pseudomyxoma peritonei and the prognostic importance of PINCH protein. Anticancer Res 32(4):1443–1448PubMed Andreasson H, Wanders A, Sun XF, Willen R, Graf W, Nygren P, Glimelius B, Zhang ZY, Mahteme H (2012) Histopathological classification of pseudomyxoma peritonei and the prognostic importance of PINCH protein. Anticancer Res 32(4):1443–1448PubMed
Zurück zum Zitat Bradley RF, Stewart JH IV, Russell GB, Levine EA, Geisinger KR (2006) Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 30(5):551–559PubMedCrossRef Bradley RF, Stewart JH IV, Russell GB, Levine EA, Geisinger KR (2006) Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 30(5):551–559PubMedCrossRef
Zurück zum Zitat Campbell-Thompson M, Lynch IJ, Bhardwaj B (2001) Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 61(2):632–640PubMed Campbell-Thompson M, Lynch IJ, Bhardwaj B (2001) Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 61(2):632–640PubMed
Zurück zum Zitat Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Malignancy Group (2012) Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 23(6):1494–1498. doi:10.1093/annonc/mdr477 PubMedCrossRef Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Malignancy Group (2012) Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 23(6):1494–1498. doi:10.​1093/​annonc/​mdr477 PubMedCrossRef
Zurück zum Zitat Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E, Women’s Health Initiative Investigators (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004. doi:10.1056/NEJMoa032071 PubMedCrossRef Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E, Women’s Health Initiative Investigators (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004. doi:10.​1056/​NEJMoa032071 PubMedCrossRef
Zurück zum Zitat Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gomez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, Gonzalez-Moreno S, Van Der Speeten K, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456. doi:10.1200/jco.2011.39.7166 PubMedCrossRef Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gomez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, Gonzalez-Moreno S, Van Der Speeten K, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456. doi:10.​1200/​jco.​2011.​39.​7166 PubMedCrossRef
Zurück zum Zitat Elias D, Gilly F, Quenet F, Bereder J, Sidéris L, Mansvelt B, Lorimier G, Glehen O (2010a) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol (EJSO) 36(5):456–462CrossRef Elias D, Gilly F, Quenet F, Bereder J, Sidéris L, Mansvelt B, Lorimier G, Glehen O (2010a) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol (EJSO) 36(5):456–462CrossRef
Zurück zum Zitat Elias D, Gilly F, Quenet F, Bereder JM, Sideris L, Mansvelt B, Lorimier G, Glehen O, Association Française de Chirurgie (2010b) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36(5):456–462. doi:10.1016/j.ejso.2010.01.006 PubMedCrossRef Elias D, Gilly F, Quenet F, Bereder JM, Sideris L, Mansvelt B, Lorimier G, Glehen O, Association Française de Chirurgie (2010b) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36(5):456–462. doi:10.​1016/​j.​ejso.​2010.​01.​006 PubMedCrossRef
Zurück zum Zitat Froggatt NJ, Green J, Brassett C, Evans DG, Bishop DT, Kolodner R, Maher ER (1999) A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet 36(2):97–102PubMedCentralPubMed Froggatt NJ, Green J, Brassett C, Evans DG, Bishop DT, Kolodner R, Maher ER (1999) A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet 36(2):97–102PubMedCentralPubMed
Zurück zum Zitat Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical Association (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618. doi:10.1002/cncr.25356 PubMedCrossRef Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical Association (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618. doi:10.​1002/​cncr.​25356 PubMedCrossRef
Zurück zum Zitat Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O’Brien PC, van Heerden JA (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219(2):112–119PubMedCentralPubMedCrossRef Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O’Brien PC, van Heerden JA (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219(2):112–119PubMedCentralPubMedCrossRef
Zurück zum Zitat Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Climacteric 2(3):239–240CrossRef Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Climacteric 2(3):239–240CrossRef
Zurück zum Zitat Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374PubMedCrossRef Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374PubMedCrossRef
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef
Zurück zum Zitat McArdle C, McMillan D, Hole D (2003) Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 90(6):711–715PubMedCrossRef McArdle C, McMillan D, Hole D (2003) Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 90(6):711–715PubMedCrossRef
Zurück zum Zitat Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG (2005) Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241(2):300–308PubMedCentralPubMedCrossRef Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG (2005) Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241(2):300–308PubMedCentralPubMedCrossRef
Zurück zum Zitat Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH (2003) Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 27(8):1089–1103PubMedCrossRef Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH (2003) Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 27(8):1089–1103PubMedCrossRef
Zurück zum Zitat National Cancer Institute (1999) National Cancer Institute common toxicity criteria version 2. The National Cancer Institute National Cancer Institute (1999) National Cancer Institute common toxicity criteria version 2. The National Cancer Institute
Zurück zum Zitat Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19(12):1390PubMedCrossRef Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19(12):1390PubMedCrossRef
Zurück zum Zitat Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92(1):85–91PubMedCrossRef Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92(1):85–91PubMedCrossRef
Zurück zum Zitat Ung L, Chua TC, Morris DL (2013) Peritoneal metastases of lower gastrointestinal tract origin: a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy. J Cancer Res Clin Oncol. doi:10.1007/s00432-013-1517-y Ung L, Chua TC, Morris DL (2013) Peritoneal metastases of lower gastrointestinal tract origin: a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy. J Cancer Res Clin Oncol. doi:10.​1007/​s00432-013-1517-y
Zurück zum Zitat van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA (2003) Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 29(8):682–688PubMedCrossRef van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA (2003) Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 29(8):682–688PubMedCrossRef
Zurück zum Zitat Wichmann M, Müller C, Hornung H, Lau-Werner U, Schildberg F (2001) Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 88(8):1092–1098PubMedCrossRef Wichmann M, Müller C, Hornung H, Lau-Werner U, Schildberg F (2001) Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 88(8):1092–1098PubMedCrossRef
Metadaten
Titel
The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre
verfasst von
Lawson Ung
Terence C. Chua
David L. Morris
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1633-3

Weitere Artikel der Ausgabe 6/2014

Journal of Cancer Research and Clinical Oncology 6/2014 Zur Ausgabe

Original Article – Clinical Oncology

Primary malignant cardiac tumors

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.